Abstract
Percutaenous closure of atrial septal defects has become common place over the last 10 years. Patients with ASDs are at risk of atrial fibrillation and heart failure as the years progress and although little categorical evidence exists, expert consensus recommends closure of ASDs which are large enough to cause either symptoms or any change in right ventricular chamber size. The HELEX and in particular AMPLAZTER devices are well suited to device closure of ASDs, with high efficacy, low procedureal complication rates and very low long term complications rates. Patients with ASDS are now routinely considered for percutaneous rather than surgical closure of ASDs, though some requirement for surgery still exists amond patients with either very large ASDs or devicient inferior rims.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Drug Targets - Cardiovascular & Hematological Disorders
Current Medicinal Chemistry - Cardiovascular & Hematological Agents
Current Cardiology Reviews
Current Hypertension Reviews
Cardiovascular & Hematological Agents in Medicinal Chemistry
Cardiovascular & Hematological Disorders-Drug Targets
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents